Design, Synthesis, and Biological Evaluation of a Novel Series of 4-Guanidinobenzoate Derivatives as Enteropeptidase Inhibitors with Low Systemic Exposure for the Treatment of Obesity-Reference-Cited by-同舟云学术

Design, Synthesis, and Biological Evaluation of a Novel Series of 4-Guanidinobenzoate Derivatives as Enteropeptidase Inhibitors with Low Systemic Exposure for the Treatment of Obesity

Published:2022-06-10 Issue:12 Volume:65 Page:8456-8477
ISSN:0022-2623
Container-title:Journal of Medicinal Chemistry
language:en
Short-container-title:J. Med. Chem.

Author:

Ikeda Zenichi¹^ORCID,Kakegawa Keiko¹,Kikuchi Fumiaki¹,Itono Sachiko¹,Oki Hideyuki¹,Yashiro Hiroaki¹,Hiyoshi Hideyuki¹,Tsuchimori Kazue¹,Hamagami Kenichi¹,Watanabe Masanori²,Sasaki Masako¹^ORCID,Ishihara Youko³,Tohyama Kimio¹,Kitazaki Tomoyuki¹,Maekawa Tsuyoshi²,Sasaki Minoru¹

Affiliation:

1. Research, Takeda Pharmaceutical Company Limited, 26-1, Muraokahigashi 2-chome, Fujisawa, Kanagawa 251-8555, Japan

2. Research Division, SCOHIA PHARMA, Inc., 26-1, Muraokahigashi 2-chome, Fujisawa, Kanagawa 251-8555, Japan

3. Pharmaceutical Sciences, Takeda Pharmaceutical Company Limited, 26-1, Muraokahigashi 2-chome, Fujisawa, Kanagawa 251-8555, Japan

Publisher

American Chemical Society (ACS)

Subject

Drug Discovery,Molecular Medicine

Link

https://pubs.acs.org/doi/pdf/10.1021/acs.jmedchem.2c00463

Reference39 articles.

1. Prevalence of Obesity, Diabetes, and Obesity-Related Health Risk Factors, 2001